Skip to Page Content

Building Sustainable Value Through New Relationships

As it searches for innovation to fuel sustainable growth, biopharma is dramatically reinventing its relationships across the board. Once entirely confident of its own strengths, the industry is displaying a new sensitivity to creative collaboration. Adaptive business models are selectively emerging. As parts of the heavily interdependent life sciences ecosystem undergo multi-year transformations, Big Pharma is acknowledging its responsibilities in propping up valuable, but capital-starved sources of long-term innovation. Getting closer to the patient is vital to the process. The result is novel cooperation among traditionally wary constituents: pharma, biotech, payers, providers and patients.

But can these arrangements, which aim to provide all parties with rewards and mitigate risk at various steps of the process deliver on value in a resource-constrained world? As pharma reaches further into emerging geographies, how does it balance growth in new markets with still-lucrative but shrinking opportunities at home? At this year's Pharmaceutical Strategic Alliances meeting we'll explore how companies can best use non-traditional partners to transform weak pipelines, jumpstart flagging revenues, and prove relevancy of their products to payers and health care providers.

Traditional alliances still have their place, though they represent a much smaller part of the strategic spectrum. Large drug companies are as apt to build relationships with venture capital partners, payers, data providers, academic centers, governments, and each other. These new relationships will generate ideas about industry's best paths forward – and create new pressures to find common ground with unfamiliar partners.

Why do so many pharma companies send their leadership teams to PSA?

PSA offers case studies about today's top biopharma issues from CEOs, Senior R&D and Senior Business Development executives. Not only will they share lessons learned, and practical advice for sealing a deal, but these key opinion leaders will debate the issues that are top of mind -- from enhancing R&D productivity to doing more with less in Business Development. In addition, attendees will also have the chance to:

  • Meet potential partners and network in a relaxed setting
  • Understand externalization models and see how a company's approach meshes with potential partners
  • Benchmark the firm's dealmaking strategy against its competitors
  • Understand the specifics driving biopharma dealmaking to better calibrate ongoing negotiations

PSA is the only meeting to gather in one place the industry's top thinkers to explain solutions to the fundamental challenges facing biotech and pharma. In a limited period of time, it will equip dealmakers like you with the insights, information and practical advice you need to strike successful deals. This program will sell out so register early. Space is limited, so register today!

At this year's event you'll hear from, and be able to quiz, top industry executives and dealmakers about the following topics:

  • Keying on the Provider System to Establish Drug/Dx Value
  • Bringing Innovation from Emerging Markets back to Headquarters
  • Neglected Diseases: Expanding your R & D, Partnering, and Investment Footprint
  • Building Biotech Value: New Models for Modern Times
  • Business Development: Do More with Less
  • Maximizing Value in a New Commercial Landscape

Benchmark your corporate strategies against the best and the brightest.

The BIGGEST Names Send their Leadership Teams to PSA. And the hotel always sells out. Unprecedented networking.
  • Abbott
  • Allergan Inc.
  • AstraZeneca
  • Bayer Healthcare
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co.
  • Eli Lilly & Company
  • Genentech
  • Genzyme
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Hoffmann-La Roche
  • Merck and Company
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi
  • UCB Pharma SA

Attend the ONLY strategic-level conference that delivers 100% case studies by the most important people in the business.

Feedback About PSA

The moderators had done their homework with the respective panels. The format was much more informative and allowed a healthy debate on the various topics discussed."
- Sam Rasty, PhD Director, Corporate Development, Endo Pharmaceuticals
PSA has an unique structure, participants and venue for top Pharma executives, which address the most relevant issues to the industry today. A must-event for pharma executives who want to move forward in the right direction."
- Robert DeBenedetto, CEO, SFJ Pharmacueticals, Inc.
Well organized. Well attended. Moderators kept panel members focused on relevant topics; good balance between high-level and details. Great way to meet key decision makers."
- Peter Kolchinsky, Managing Partner, RA Capital
Very good information presented during the the panel sessions. Excellent participants with a clear understanding and influence of future pharma/biotech trends."
- Joe Panegasser, Director, Alliance Management PPD Inc.